摘要
目的:探讨血清IL-32在不同严重程度的慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)急性期和稳定期患者中的表达及其与病情轻重的相关性。方法:收集Ⅰ、Ⅱ、Ⅲ、Ⅳ级不同严重程度的COPD和AECOPD(治疗前及治疗后)患者及健康对照组各30例血清,通过ELASA法检测各自血清IL-32浓度,并比较组间和组内差异,分析血清IL-32浓度与FEV1占预计值百分比、FEV1/FVC相关性。结果:①IL-32在9组人群治疗前的浓度差异:AECOPD组IL-32血清浓度水平较健康对照组、COPD稳定期组均显著升高(P均<0.01);COPD稳定期组较健康对照组IL-32血清浓度水平显著升高(P<0.05);COPD稳定期及AECOPD组Ⅰ、Ⅱ、Ⅲ、Ⅳ级各组间IL-32血清浓度均有显著差异,随病情严重程度的增加表达水平逐渐升高(P均<0.01或<0.05);②IL-32在AECOPD各组人群治疗前、后的浓度差异:AECOPD组Ⅰ、Ⅱ、Ⅲ、Ⅳ级各组治疗后IL-32血清浓度水平较治疗前均显著下降(P均<0.01);治疗后AECOPD各组间仍有显著差异,仍随病情严重程度的增加表达水平逐渐升高(P均<0.01或<0.05);③AECOPD各组治疗前、后患者血清IL-32浓度与FEV1%pred、FEV1/FVC均呈负相关(r值分别为-0.75、-0.87和-0.66、-0.81,P均<0.01),COPD稳定期各组患者血清IL-32浓度与FEV1%pred、FEV1/FVC均呈负相关(r值分别为-0.58和-0.74,P均<0.01)。结论:IL-32参与了COPD的炎症过程,参与了COPD患者急性加重的炎症反应;血清IL-32浓度与COPD患者FEV1%pred、FEV1/FVC呈负相关,在一定程度上反应COPD病情严重程度。IL-32可作为COPD病情评估和疗效评价指标之一,并可能成为COPD未来治疗的新方向之一。
Objective：To investigate the relationship and significance of IL-32 in the Serum in Chronic Obstructive Pulmonary Dis ease. Methods： To collect serum of different severity of COPD and AECOPD （before treatment and after treatment） patients and healthy control group of 30 cases. Use the method of ELISA to detect the serum level of IL-32 in healthy control group and groups of varying severity in patients with COPD and AECOPD. To compare the differences within and among groups, analyze the correla- tion of serum 1L-32 concentration and percent predicted FEV1, FEV1/FVC. Results：There is significantly increased in the serum level of IL-32 in AECOPD group as compared with healthy control group and COPD stable group（P〈0.01）. There is significantly higher in the serum level of IL-32 between COPD group and the healthy control group（P〈0.05）. There are significantly different in different severity of COPD and AECOPD patients （r=-0.87;-0.58,P〈0.01 or P〈0.05）, the more severe the higher. Conclu- sion：IL 32 may be involved in the pathogenesis of airway inflammation in COPD and AECOPD. There is negative correlation be- tween IL 32 and percent predicted FEV1 and FEV1/FVC of COPD. To some extent, IL-32 responses the severity of COPD. IL-32 may be a noninvasive marker of severity and evaluation of COPD. IL-32 may be a new direction of the treatment for COPD in future.
出处
《亚太传统医药》
2014年第6期6-8,共3页
Asia-Pacific Traditional Medicine
基金
佛山市卫生局医学科研计划项目(2012224)
关键词
慢性阻塞性肺疾病
稳定期
急性加重期
血清IL-32
Acute Exacerbation of Chronic Obstructive Pulmonary Disease（AECOPD）
Chronic Obstructive Pulmonary Disease （COPD）
IL-32
